Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002389 | 0.83 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL28984515 | 0.81 | SLC6A3 (0.61) | SLC6A3SLC6A4SLC6A2HSD11B1 | |
| SCHEMBL12000469 | 0.79 | SLC6A3 (0.54) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL12002387 | 0.79 | SLC6A3 (0.62) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL21041893 | 0.79 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL8977327 | 0.78 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL435013 | 0.78 | HSD11B1 (0.68) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL14944312 | 0.77 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL9013692 | 0.76 | SLC6A3 (0.55) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 | |
| SCHEMBL9013661 | 0.76 | SLC6A3 (0.55) | SLC6A3SLC6A4SLC6A2HSD11B1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597089-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |